Fischer Medical Ventures shines as its arm enters into partnership with Parul Sevashram Hospital
Fischer Medical Ventures is currently trading at Rs. 39.68, up by 0.87 points or 2.24% from its previous closing of Rs. 38.81 on the BSE.
The scrip opened at Rs. 39.50 and has touched a high and low of Rs. 40.22 and Rs. 37.65 respectively. So far 101911 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 124.20 on 24-Sep-2025 and a 52 week low of Rs. 31.13 on 09-Jun-2026.
Last one week high and low of the scrip stood at Rs. 40.22 and Rs. 35.38 respectively. The current market cap of the company is Rs. 2578.14 crore.
The promoters holding in the company stood at 62.15%, while Institutions and Non-Institutions held 6.83% and 31.02% respectively.
Fischer Medical Ventures’ wholly owned subsidiary -- Time Medical International Ventures (India) has entered into a partnership with Parul Sevashram Hospital, Vadodara, to install its revolutionary DRIS-iMRI Medharanya Suite, an AI-enabled next-generation portable intraoperative MRI system.
Time Medical has developed a revolutionary new variant of MRI imaging technology--DRIS-iMRI Medharanya, an AI-enabled, next-generation, portable and specialized MRI system integrating Augmented Reality (AR), Artificial Intelligence (AI), Machine Learning (ML), and Exoscope technologies. The intraoperative MRI platform is designed to transform intraoperative imaging by providing surgeons with real-time visualization during complex neurosurgical procedures, enabling unprecedented precision, safety, and surgical control in procedures that traditionally rely on limited visual feedback.
Time Medical International Ventures has entered into a partnership to install its first Modern Brain Suite: the DRIS-iMRI Medharanya system at Parul Sevashram Hospital, Vadodara. Parul Sevashram Hospital’s vision of ‘Health for All’ and its commitment to accessible, high-quality healthcare closely aligns with TMIV’s focus on expanding access to advanced imaging technologies and improving clinical outcomes through innovation-driven diagnostics and interventional solutions.
